Table 4

Crude and adjusted associations of number of citrullinated protein antibodies with CT expert read Interstitial Lung Disease Score

Model 1Model 2Model 3Model 4Model 5
β*p Valueβ*p Valueβ*p Valueβ*p Valueβ*p Value
No of high level ACPA, per antibody0.100.001
High level ACPA=0 (n=50)RefRefRefRef
High level ACPA=1 or 2 (n=43)0.310.430.360.350.390.27−0.260.58
High level ACPA=3–6 (n=41)0.450.260.300.470.360.33−0.360.46
High level ACPA≥ 7 (n=42)1.280.0010.790.0550.930.0120.230.63
Age, per year0.0340.0350.0340.0320.0360.022
Male vs female0.490.120.540.0550.450.12
Ever smoking0.780.0100.700.0170.750.011
Current smoking0.830.0610.930.0330.900.038
RF seropositivity0.250.43
Square root DAS28, per unit1.350.0131.360.0051.330.006
Log SHS, per unit−0.060.61
Rheumatoid nodules0.340.22
HAQ, per unit−0.140.53
Current prednisone0.440.120.530.0530.440.11
Current methotrexate−0.310.30
Current leflunomide1.200.0071.240.0041.240.004
Current biologics0.260.37
CCP2>20 units0.960.035
  • *β coefficients represent the average change in the square root of the expert read Interstitial Lung Disease Score associated with a 1 unit higher value of the characteristic of interest. Statistical comparisons from linear regression.

  • ACPA, anticitrullinated protein antibody; CCP2, second generation commercial anticyclic citrullinated peptide assay; DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SHS, Sharp-van der Hiejde Score.